Advice
in the absence of a submission from the holder of the marketing authorisation:
parathyroid hormone (Natpar®) is not recommended for use within NHS Scotland.
Indication under review: As adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice135KB (PDF)
Medicine details
- Medicine name:
- parathyroid hormone (Natpar)
- SMC ID:
- 1334/18
- Indication:
- As adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.
- Pharmaceutical company
- Shire Pharmaceuticals
- BNF chapter
- Endocrine system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 09 April 2018